Back to Search Start Over

The Exploitation of pH-Responsive Eudragit-Coated Mesoporous Silica Nanostructures in the Repurposing of Terbinafine Hydrochloride for Targeted Colon Cancer Inhibition: Design Optimization, In Vitro Characterization, and Cytotoxicity Assessment.

Authors :
Alyami, Mohammad H.
Musallam, Abeer A.
Ibrahim, Tarek M.
Mahdy, Mahmoud A.
Elnahas, Hanan M.
Aldeeb, Reem A.
Source :
Pharmaceutics. Dec2023, Vol. 15 Issue 12, p2677. 23p.
Publication Year :
2023

Abstract

Targeted drug delivery is achieving great success in cancer therapy due to its potential to deliver drugs directly to the action site. Terbinafine hydrochloride (TER) is a broad-spectrum anti-fungal drug that has been found to have some potential anti-tumor effects in the treatment of colon cancer. We aimed here to design and develop pH-sensitive Eudragit (Eud)-coated mesoporous silica nanostructures (MSNs) to control drug release in response to changes in pH. The diffusion-supported loading (DiSupLo) technique was applied for loading TER into the MSNs. The formulation was optimized by a D-optimal design, which permits the concurrent assessment of the influence of drug/MSN%, coat concentration, and MSN type on the drug entrapment efficiency (EE) and its release performance. The optimal formula displayed a high EE of 96.49%, minimizing the release in pH 1.2 to 16.15% and maximizing the release in pH 7.4 to 78.09%. The cytotoxicity of the optimal formula on the colon cancer cells HT-29 was higher than it was with TER alone by 2.8-fold. Apoptosis in cancer cells exposed to the optimum formula was boosted as compared to what it was with the plain TER by 1.2-fold and it was more efficient in arresting cells during the G0/G1 and S stages of the cell cycle. Accordingly, the repurposing of TER utilizing Eud/MSNs is a promising technique for targeted colon cancer therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19994923
Volume :
15
Issue :
12
Database :
Academic Search Index
Journal :
Pharmaceutics
Publication Type :
Academic Journal
Accession number :
174463537
Full Text :
https://doi.org/10.3390/pharmaceutics15122677